Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

What Physicians Want: Less of Promotional Content

Spain Reps Tick Right Boxes

Executive Summary

Healthcare professionals are inundated by product-related promotional content from pharma firms and want less of that but more on areas such as safety, efficacy and real-world evidence, a new survey on engaging digitally-savvy physicians indicates. Spain emerges as a stand-out market where pharma appears to have fared relatively well in mapping physician preferences to their marketing activities.

You may also be interested in...



Boehringer Ingelheim’s Formula For Scaling Transformation, Digitization

Boehringer Ingelheim’s corporate senior vice president, head of global regions, Timmo Rousku Andersen, outlines at a recent summit the company’s reshaped approach to digital innovation and the need to entrench an execution bias to scale transformation initiatives.

Boehringer Will Go 'Wide, Broad, Fast, Strong' If Jardiance Hits CKD Bullseye

Data is the new gold and Timmo Rousku Andersen, Boehringer Ingelheim’s corporate senior vice-president, head of global regions, outlines in an interview the German group's efforts to shape go-to-market models driven by data and insights. He also touches on digital therapeutics and how the firm’s R&D engine is pursuing deeper insights into interconnected disorders.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: Scrip asks what 2022 holds for deal-making; Pfizer looks for transactions to add to its top line; Sanofi unworried about JAK threat to Dupixent; what information do healthcare professionals want from pharma; and Amgen looks to its established brands for growth.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC145843

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel